NY Times
MAY 5, 2021
The Biden administration, siding with some world leaders over the U.S. pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines.
pharmaphorum
MAY 7, 2021
Reports are emerging that the UK may join other countries in imposing restrictions on the use of AstraZeneca’s COVID-19 vaccine in younger people, after a fresh look at the risks and benefits of the shot. . The Joint Committee on Vaccination and Immunisation (JCVI) said last month that it is preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AZ/Oxford University adenovirus-based vaccine where available.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
MAY 4, 2021
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
Outsourcing Pharma
MAY 3, 2021
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NY Times
MAY 7, 2021
State lawmakers have voted to add the firing squad as an alternative to the electric chair or lethal injection, with the drugs used for capital punishment in short supply.
pharmaphorum
MAY 6, 2021
UK-based performance-io has added to its senior team through two promotions and the appointment of STEM Healthcare CEO Jason McKenna as a non-executive director. He will oversee the online performance marketing and digital benchmarking agency’s growth in the US joins Rob Wood and Barrie Brien on performance-io’s non-executive board. McKenna has been with STEM since 2010, founding it in the US and Brazil before taking over the CEO role from co-founder Rob Wood in 2018.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
MAY 5, 2021
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are nineteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
MAY 7, 2021
Sinopharm is the first Chinese shot to be classified as safe and effective by the World Health Organization, allowing the vaccine to be more widely distributed to poor and middle-income nations.
pharmaphorum
MAY 6, 2021
UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready for human testing within 12 months. . The start-up is focusing on processed and purified extracts from an undisclosed plant source that have been shown in lab studies to kill the SARS-CoV-2 virus, and also have potential applications in other respiratory infections.
Pharma Times
MAY 6, 2021
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
MAY 3, 2021
Annual Drug Patent Expirations for ATRIPLA Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from two suppliers. There are nine patents…. The post New patent expiration for Gilead Sciences drug ATRIPLA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
MAY 5, 2021
The Biden administration, siding with some world leaders over the U.S. pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines.
pharmaphorum
MAY 4, 2021
The life sciences history industry has some unique challenges when it comes to compliance. But if you think third party compliance risks are bad, don’t take your eye off fourth and fifth parties, says Allan Matheson. Early life science pioneers in foreign markets earned a reputation for lax ethical behaviour, making them a prime target for regulators.
Pharma Times
MAY 4, 2021
Targeting a specific mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients
Outsourcing Pharma
MAY 3, 2021
According to a recent survey of executives conducted by CPhI, COVID-19âs impact is driving manufacturing and CDMOs are fueling industry growth.
NY Times
MAY 4, 2021
The company said it also plans to apply this month for full F.D.A. approval — not just emergency authorization — for the vaccine’s use in adults.
pharmaphorum
MAY 5, 2021
Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines. . The company also said that it doesn’t expect the massive sales to be a one-off, as demand from governments around the world for coronavirus vaccines will continue to be strong in the coming years.
Pharma Times
MAY 5, 2021
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
Outsourcing Pharma
MAY 6, 2021
This monthâs roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
NY Times
MAY 7, 2021
The vaccine has been used under an emergency authorization since December. A decision by the Food and Drug Administration could take months.
pharmaphorum
MAY 5, 2021
A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the organisation developing it. . The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) is leading the development of MDMA and has just reported top-line results from a phase 3 trial of the drug combined with psychotherapy that it says could form the basis of a marketing application to the US reg
Pharma Times
MAY 6, 2021
MSF has applauded the move, but the IFPMA said the decision is “disappointing”
Outsourcing Pharma
MAY 3, 2021
A leader from the mobile research nursing specialist offers advice on what to look for in a service provider, and why finding the right one is vital.
NY Times
MAY 7, 2021
The vaccine has been used under an emergency authorization since December. A decision by the Food and Drug Administration could take months.
pharmaphorum
MAY 4, 2021
AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD). . The US regulator has cleared Farxiga (dapagliflozin) to reduce the risk of kidney damage, end-stage kidney disease, cardiovascular, death and hospitalisation for heart failure in adults with CKD who are at risk of progression.
Pharma Times
MAY 5, 2021
Managed access agreement treatment eligibility criteria extended following review
Drug Patent Watch
MAY 7, 2021
Annual Drug Patent Expirations for COSELA Cosela is a drug marketed by G1 Therap and is included in one NDA. There are eight patents protecting this drug. This drug has…. The post New patent for G1 Therap drug COSELA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
MAY 3, 2021
President Biden and drugmakers are facing demands from liberal activists and global leaders to suspend intellectual property rights on the vaccines as the pandemic surges.
pharmaphorum
MAY 6, 2021
Shares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents on them, a moved aimed to boost global supplies of the life-saving shots. Waiving the patent on proprietary knowledge would allow it to be shared with other manufacturers and the matter is being discussed by the World Trade Organization’s General Council today.
Pharma Times
MAY 7, 2021
The deal will see Vectura test Inspira's inhaled IPX formulation candidates
Pharma Mirror
MAY 6, 2021
Are you catching yourself turning the volume up when listening to the radio or watching a TV show? Have thought about what might be the reason behind that, or have you just assumed that it is perfectly normal and that there is absolutely no reason to worry about anything? If it’s the latter, then I suggest you think twice. The simple truth is that this can actually be a rather serious problem and even if it’s not, your decision to ignore it will most definitely make it serious.
NY Times
MAY 4, 2021
The company said its vaccine generated $3.5 billion in revenue in the first three months of this year.
pharmaphorum
MAY 7, 2021
Antoinette Bobbitt has been promoted to executive vice president, strategy director at independent US creative agency, The Bloc. As EVP, Strategy Director, Antoinette will be responsible for ensuring that the agency’s talent, planning methodology, and tools are aligned with the Bloc’s vision of building exceptional customer experiences. She will oversee the strategy for several clients, and she’ll manage a team that works across all business units in order to ensure The Bloc’s competitive differ
Pharma Times
MAY 5, 2021
Funds will be used to advance company's integrated physiological and digital biomarker platform
Drug Channels
MAY 7, 2021
Today’s guest post comes from Jill Brown Kettler, Executive Editor at AIS Health, a division of MMIT. Jill discusses MMIT's proprietary data on how the COVID-19 pandemic affected enrollment in commercial plans, Medicaid, and health insurance exchanges. . To learn more about 2020 enrollment changes and the 2021 outlook, register for MMIT’s free webinar on May 18 at 1:00 pm ET: Meet the Expert: Predicting Enrollment Changes in the Covid Era.
Expert insights. Personalized for you.
140 
Let's personalize your content